Staidson (Beijing) Biopharmaceuticals Co Ltd
300204
Company Profile
Business description
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
Contact
Rongjing Dong Street
No 5 Beijing Economic and Technological Development Zone
Beijing100176
CHNT: +86 1067862266
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
492
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,874.64 | 24.21 | 0.31% |
| DAX 40 | 24,476.31 | 235.49 | 0.97% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,152.53 | 91.04 | 1.00% |
| HKSE | 25,667.18 | 129.11 | 0.51% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |